… In the AMPLIFY trial, apixaban was non-inferior to warfarin in prevention … efficacy of apixaban
and warfarin in reducing risk of VTE recurrence, with lower risk of bleeding in the apixaban …

… Therefore, the aim of this study was to evaluate the effectiveness and safety of DOACs
versus warfarin for the treatment of acute venous thromboembolism (VTE) in obese patients. …

… However, their use in the treatment of acute venous thromboembolism (VTE) in morbidly
obese patients (bodyweight of > 120 kg or BMI > 40 kg/m 2 ) guarded. This is due to the scarce …

… effectiveness of apixaban versus warfarin for the prevention of recurrent VTE and (2) examine
the difference in major bleeding risk in patients with VTE receiving apixaban and warfarin. …

… These agents are recommended regardless of patient weight … the use of apixaban in patients
with severe obesity with a BMI … the efficacy and safety of apixaban for VTE in patients with a …

… Safety, effectiveness, and health care cost comparisons among elderly patients with
venous thromboembolism prescribed warfarin or apixaban in the United States Medicare …

The study objective was to evaluate the safety and effectiveness of dabigatran and other
direct oral anticoagulants (DOACs) compared with warfarin among patients with nonvalvular …

… Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus
warfarin for the treatment of acute venous thromboembolism: a pooled analysis from re‐cover …

… thromboembolic conditions, we aimed to compare the efficacy and safety of DOACs with
warfarin in the post-acute … efficacy in the treatment of deep vein thrombosis (DVT), pulmonary …

… We included all trials investigating efficacy and safety of the DOACs in patients with acute
VTE, aiming to provide a comprehensive picture for the comparative treatment effect of DOACs …